Walgreens sells majority of Alliance Healthcare pharmacy business to AmerisourceBergen in $6.5 billion deal
Walgreens Boots Alliance Inc. WBA,
The transaction includes $6.275 billion in cash and two million shares of AmerisourceBergen common stock. It is expected to close by the end of AmerisourceBergen’s fiscal 2021.
Revenue in fiscal 2020 for the businesses sold totaled $19 billion.
See: These are the best performing Nasdaq and S&P 500 stocks of 2020
In a statement, the companies say the deal will provide support for pharmacies and pharmacists through AmerisourceBergen, and Walgreens will now be free to increase its focus on its core retail pharmacy business.
The deal also expands AmerisourceBergen’s business in Europe.
The two companies have partnered since 2013, and Walgreens is AmerisourceBergen’s largest stockholder with a 30% stake.
The news sent shares of Walgreens up 2% in premarket trading, while AmerisourceBergen shares jumped 6.4%.
In addition to the pharmacy transaction, the two companies have also extended their U.S. distribution agreement three years until 2029, with annual run-rate synergies expected to reach $150 million, which will be shared equally by both companies. And Alliance Healthcare UK will continue as Walgreens distribution partner until 2031.
Watch: 3 things to know about the COVID-19 vaccine supply chain
The deal is expected to be add to AmerisourceBergen’s adjusted earnings per share in the first fiscal year.
Walgreens expects expects the transaction to be “slightly dilutive” in the current financial year and accretive in the long term.
AmerisourceBergen also updated its fiscal 2021 guidance, forecasting adjusted EPS in the range of $8.25 to $8.50, up from previous guidance of $8.20 to $8.45.
The updated guidance does not include contribution from the Alliance Healthcare deal with Walgreens.
The FactSet consensus is for EPS of $8.42.
Walgreens stock has slumped nearly 31% over the past year. AmerisourceBergen has gained 14.7% just shy of the benchmark S&P 500 index’s SPX,
